SynthesisNeurocritical care2026
Early Versus Late Initiation of Chemical Venous Thromboembolism Prophylaxis in Adult Patients with Severe Traumatic Brain Injury: A Systematic Review and Meta-analysis.
Synthesis in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with severe traumatic brain injury (TBI) are at high risk of venous thromboembolism (VTE). However, the optimal timing for initiating chemical VTE prophylaxis (cVTEp) remains controversial due to concerns for intracranial hemorrhage progression.
methodsFive databases were searched (inception to October 2024) for studies evaluating early versus late cVTEp initiation in severe TBI (defined as Glasgow Coma Scale score ≤ 8 or Abbreviated Injury Scale score ≥ 3). Data were extracted independently and pooled using random-effects models. Early versus late cVTEp initiation and stratified analyses (for cutoffs at ≤ 24, ≤ 48, and ≤ 72 h) were performed, and odds ratios (ORs) were calculated. Outcomes included VTE, hemorrhage progression, neurosurgical intervention, and in-hospital mortality. Absolute risk reduction (ARR) was calculated using control event rates and ORs. Risk of bias was assessed by the Risk of Bias in Non-Randomized Studies-of Interventions tool.
resultsTwenty-one studies were included in the systematic review, with 14 (n = 24,401) included in the meta-analysis. Early compared to late cVTEp initiation was associated with lower odds of VTE (OR 0.47; 95% confidence interval [CI] 0.37-0.60), with consistent benefit at ≤ 48 h (OR 0.39; 95% CI 0.23-0.65) and at ≤ 72 h (OR 0.52; 95% CI 0.39-0.69) but not at ≤ 24 h (OR 0.48; 95% CI 0.14-1.60). The ARR of early vs. late initiation within each stratum was 1.2% for ≤ 24 h, 2.1% for ≤ 48 h, and 3.7% for ≤ 72 h, reflecting differences in the event rates for VTE in each stratum. No significant increase in hemorrhage progression, neurosurgical intervention, or mortality was observed. Notably, mortality was significantly lower for cVTEp initiated at ≤ 48 h (OR 0.74; 95% CI 0.63-0.87). All included studies had moderate to serious risk of bias.
conclusionsEarly cVTEp initiation in severe TBI was associated with lower odds of VTE events and a mortality benefit when initiated at ≤ 48 h. These findings support earlier cVTEp, but the results should be interpreted cautiously due to study heterogeneity and risk of bias, highlighting the need for high-quality prospective research.
Indexed as
Identifiers
41239163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.